1. Editorial

   Editorial 23 August 2016 Pages: 443 - 444

   

2. Editorial

   Editorial 23 August 2016 Pages: 445 - 445

   

3. Therapeutic drug monitoring of 5-fluorouracil

   • James J. Lee
   • Jan H. Beumer
   • Edward Chu

   Review Article 23 May 2016 Pages: 447 - 464

4. Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics

   • Ali Aboel Dahab
   • Dhia El-Hag
   • Norman W. Smith

   Review Article 09 April 2016 Pages: 465 - 489

   

5. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours

   • Amita Patnaik
   • Anthony Tolcher
   • Sunil Sharma

   Original Article 08 July 2016 Pages: 491 - 500

   

6. A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer

   • Kazuhiko Yamada
   • Masao Ichiki
   • Tomoaki Hoshino

   Original Article 11 July 2016 Pages: 501 - 507

   

7. Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients

   • Ankit Madan
   • Benjamin S. Jones
   • Francisco Robert

   Original Article 14 July 2016 Pages: 509 - 515

   

8. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil

   • Shinji Kobuchi
   • Asuka Hayashi
   • Toshiyuki Sakaeda

   Original Article 14 July 2016 Pages: 517 - 523

   

9. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

   • Kan Yonemori
   • Kenji Tamura
   • Yasuo Takahashi

   Original Article Open access 15 July 2016 Pages: 525 - 531

   

10. SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia

    • Jeong-Hyun Kim
    • Chansu Lee
    • Sung-Soo Yoon

    Original Article 15 July 2016 Pages: 533 - 540

    

11. A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer

    • D. J. Renouf
    • D. Hedley
    • M. J. Moore

    Original Article 15 July 2016 Pages: 541 - 545

    

12. Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer

    • Chunze Li
    • Bei Wang
    • Sandhya Girish

    Original Article 16 July 2016 Pages: 547 - 558

    

13. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network

    • Sumitra Shantakumar
    • Beth L. Nordstrom
    • Jeanenne Nelson

    Original Article Open access 20 July 2016 Pages: 559 - 566

14. A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab

    • Naoki Takahashi
    • Satoru Iwasa
    • Yasuhide Yamada

    Original Article 20 July 2016 Pages: 567 - 575

    

15. A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer

    • Muhammad S. Beg
    • Nilofer S. Azad
    • Michael A. Morse

    Original Article 23 July 2016 Pages: 577 - 584

    

16. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)

    • Takao Takahashi
    • Yasunori Emi
    • Kyushu Study Group of Clinical Cancer (KSCC)

    Original Article 28 July 2016 Pages: 585 - 593

    

17. Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients

    • V. Krizkova
    • M. Dubova
    • P. Soucek

    Original Article 28 July 2016 Pages: 595 - 603

    

18. Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline

    • Laurent Claret
    • Jenny Zheng
    • Rene Bruno

    Original Article 28 July 2016 Pages: 605 - 610

    

19. The molecular mechanism of action of superactive human leptin antagonist (SHLA) and quadruple leptin mutein Lan-2 on human ovarian epithelial cell lines

    • Elżbieta Fiedor
    • Ewa Łucja Gregoraszczuk

    Original Article Open access 01 August 2016 Pages: 611 - 622

    

20. BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen

    • Jung-woo Chae
    • Yi Ling Teo
    • Alexandre Chan

    Original Article 02 August 2016 Pages: 623 - 632

    

21. Myelosuppression by chemotherapy in obese patients with gynecological cancers

    • Kensuke Kamimura
    • Yoshifumi Matsumoto
    • Yasuo Saijo

    Original Article 02 August 2016 Pages: 633 - 641

    

22. SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis

    • Yanfen Chen
    • Meng Sun
    • Qubo Zhu

    Original Article 03 August 2016 Pages: 643 - 654

    

23. Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin

    • Xia Zhang
    • Weijun Bai

    Short Communication 29 July 2016 Pages: 655 - 659